Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology

Kidney International Reports 2026 Open access

Read full text
Authors: Martina Uzzo, Federica Mescia, Jennifer Scott, Jennifer O'Brien, Kres̆imir Gales̃ić, Simonetta Genovesi, Giorgio Trivioli, Marco Allinovi, Iva Gunnarsson, Anna Juto, Robert L. Hall, Ingeborg M. Bajema
+12 more Silke R. Brix, Vincenzo L’Imperio, Andreas Kronbichler, Annette Bruchfeld, Gaetano La Manna, Mario Cozzolino, Renato A. Sinico, Matija Crnogorac, Stephen P. McAdoo, Mark A. Little, David Jayne, Federico Alberici
DOI: 10.1016/j.ekir.2026.103776
Cited by: 2
References: 29

Abstract

Introduction Cyclophosphamide (CYC) and rituximab (RTX), alone or combined, are the mainstays of induction therapy in ANCA-glomerulonephritis. It is unknown whether the response to induction is differentially affected by kidney histopathology. Methods This is a retrospective, multicenter study including patients with biopsy-proven ANCA-glomerulonephritis. Cases were grouped according to the Berden nephropathology classification. eGFR recovery at 6 months was defined as eGFR increase≥15ml/min/1.73m 2 or discontinuation of kidney replacement therapy; kidney failure was defined as sustained eGFR

Fields of Study & Subjects

Vasculitis and related conditions Renal Diseases and Glomerulopathies Amyloidosis: Diagnosis Treatment Outcomes

Publication details

Journal / source
Kidney International Reports
Publisher
Elsevier BV
Volume
11
Issue
3
Pages
103776–103776
Publication date
13 January 2026
Language
EN